Advanced Search

 

Study ID Status Title Patient Level Data
101560 Completed A Dose Ranging Study to Evaluate the Pharmacokinetics of an SB 480848 Freebase Enteric Coated Formulation
101582 Completed A Study to Assess the Effects of Food and Repeat Dosing of Esomeprazole on the Pharmacokinetics of a Single Dose of Freebase Enteric Coated SB 480848
101597 Completed A Study to Evaluate the Effect of Repeat Oral Doses of SB-480848 on Platelet Function as Compared to Placebo
101682 Completed A randomised, double-blind, placebo-controlled, parallel group study to examine the safety, tolerability, and pharmacokinetics of repeat inhaled doses of GSK159797 in healthy subjects.
101695 Ext. Mth30 Completed Long-term study of immune response persistence of GSK Biologicals' 2-dose thiomersal-free Engerix™-B and 3-dose preservative-free Engerix™-B vaccines in subjects aged 11-15 yrs Study Listed on ClinicalStudyDataRequest.com
101858 Completed Evaluate Immuno and Safety of GSKBiologicals' HibMenCYTT vs Licensed Hib Conjugate Vaccine, Each Coadministered With Pediarix® and Prevnar®, in Healthy Infants. An Exploratory Control Group Will Receive Licensed Menomune® at 3 to 5 years Study Listed on ClinicalStudyDataRequest.com
101877 Completed A randomised, open label, 5-way crossover study to assess the systemic exposure of FP and salmeterol from SERETIDE/ADVAIR 250 without spacer, with Aerochamber -Plus and with -Max spacer, with VOLUMATIC spacer and SERETIDE/ADVAIR 500 DISKUS/ACCUHALER in adult subjects with mild or intermittent asthma Study Listed on ClinicalStudyDataRequest.com
101888 Completed A randomised, placebo-controlled, four way crossover study to evaluate the effect of double-blind 4000 mcg of orally inhaled GW685698X and of 6.25 mg cellobiose octa-acetate on electrocardiographic parameters, with single-blind 400 mg of oral moxifloxacin as a positive control, in 40 healthy male and female subjects. Study Listed on ClinicalStudyDataRequest.com
101963 Completed A randomised, blinded, parallel group study to investigate the potential pharmacokinetic interaction between lamotrigine and risperidone in healthy, non-smoking, male volunteers. Study Listed on ClinicalStudyDataRequest.com
101998 Completed A randomized, double-blind, parallel group, placebo-controlled, single-attack evaluation of the efficacy and tolerability of TREXIMA™ (sumatriptan 85mg/naproxen sodium 500mg)* tablets vs placebo when administered during the mild pain phase of a migraine Study Listed on ClinicalStudyDataRequest.com
101999 Completed A randomized, double-blind, parallel group, placebo-controlled, single-attack evaluation of the efficacy and tolerability of TREXIMA™ (sumatriptan 85mg/naproxen sodium 500mg)* tablets vs placebo when administered during the mild pain phase of a migraine Study Listed on ClinicalStudyDataRequest.com
102038 Completed Open, phase IV clinical trial to compare the immunogenicity and reactogenicity of GSK Biologicals’ Infanrix™ (DTPa) vaccine administered as a booster dose at 4 years of age in preterm vs. full-term children previously primed and boosted with Infanrix™ hexa.
102115 Completed A dose-range study to assess the safety and immunogenicity of a novel HPV vaccine when administered intramuscularly according to a 3-dose schedule (0,1,6-month) in healthy adult females (18-25 years of age) Study Listed on ClinicalStudyDataRequest.com
102115 Completed A dose-range study to assess the safety and immunogenicity of a novel HPV vaccine when administered intramuscularly according to a 3-dose schedule (0,1,6-month) in healthy adult females (18-25 years of age) Study Listed on ClinicalStudyDataRequest.com
102123 Completed A randomised double-blind placebo controlled parallel group multicentre long term study to evaluate the safety of once-daily, intranasal administration of GW685698X aqueous nasal spray 100mcg* for 52 weeks in adult and adolescent subjects with perennial allergic rhinitis. Study Listed on ClinicalStudyDataRequest.com
102130 Completed An open-label, randomized, four-period crossover study in healthy subjects to demonstrate the bioequivalence of a fixed dose combination tablet formulation of rosiglitazone/simvastatin (8mg/80mg) to concomitant dosing of rosiglitazone 8mg and simvastatin 80mg commercial tablets and to assess the pharmacokinetics of the concomitant dosing of rosiglitazone 8mg and simvastatin 80mg commercial tablets relative to commercial rosiglitazone 8mg alone, and commercial simvastatin 80mg alone, in healthy s Study Listed on ClinicalStudyDataRequest.com
102144 Completed Study to assess immunogenicity and reactogenicity of a booster dose of GSK Biologicals Kft’s combined DTPwCSL-HB vaccine as compared to concomitant administration of CSL’s DTPw vaccine and GSK Biologicals' hepatitis B vaccine at separate injection sites and to GSK Biologicals' DTPw-HB vaccine Study Listed on ClinicalStudyDataRequest.com
102146 Completed An open-label, randomized, three-period crossover study to demonstrate the bioequivalence of sumatriptan 4 mg STATdose to IMITREX™ 6 mg STATdose after dose-normalization, and to assess the relative bioavailability of 4 mg sumatriptan injected using the STATdose device compared to 4 mg sumatripta ... Study Listed on ClinicalStudyDataRequest.com
102151 Completed Open immunization study to determine the reactogenicity and immunogenicity of Fluarix™/Influsplit SSW® 2004/2005 in persons as of 18 years of age.
102247/036 Completed A multi-country & multi-center study to assess the efficacy, safety & immunogenicity of 2 doses of GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine in healthy infants in co-administration with specific childhood vaccines Study Listed on ClinicalStudyDataRequest.com
102247/036 Annex Completed A phase IIIb, double-blind, randomized, placebo-controlled, multi-country and multi-center study to assess the efficacy, safety and immunogenicity of two doses of GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine in healthy infants in co-administration with specific childhood vaccines
102248 Completed Multi-Center Study to Assess the Efficacy, Safety and Immunogenicity of 2 or 3 Doses of GSK Biologicals' Oral Live Attenuated Human Rotavirus (HRV) Vaccine Given Concomitantly With Routine EPI Vaccinations in Healthy Infants Study Listed on ClinicalStudyDataRequest.com
102370 (primary study) Completed A multicentre primary & booster vaccination study of GSK Biologicals' Hib-MenCY-TT conjugate vaccine vs ActHIB® & MenC conjugate licensed vaccine when given according to the 2-4-6 month schedule to healthy infants with booster dose at 12 to 15 months Study Listed on ClinicalStudyDataRequest.com
102394 Completed A Phase IV, partially double-blind study to demonstrate non-inferiority of GSK Biologicals’ Mencevax™ ACWY (new process) versus Mencevax™ ACWY (current process) when administered as a single dose to subjects aged 2-30 yrs Study Listed on ClinicalStudyDataRequest.com
102499 Completed A phase III, open, randomized, multicenter, comparative vaccination study to evaluate the immunogenicity and reactogenicity of various formulations of a monovalent candidate pandemic influenza A vaccine in individuals over 60 years of age Study Listed on ClinicalStudyDataRequest.com

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.